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Abstract
Background: Diets that restrict energy or macronutrient intake (e.g. fasting/ketogenic diets (KDs)) may selectively
protect non-tumour cells during cancer treatment. Previous reviews have focused on a subset of dietary restrictions
(DR) or have not performed systematic searches. We conducted a systematic scoping review of DR at the time of
cancer treatment.
Methods: MEDLINE, Embase, CINAHL, AMED and Web of Science databases were searched for studies of adults
undergoing DR alongside treatment for cancer. Search results were screened against inclusion/exclusion criteria.
Data from included studies were extracted by two independent reviewers. Results were summarised narratively.
Results: Twenty-three independent studies (34 articles), with small sample sizes, met the inclusion criteria. Four
categories were identified: KDs (10 studies), fasting (4 studies), protein restriction (5 studies) and combined
interventions (4 studies). Diets were tolerated well, however adherence was variable, particularly for KDs. Biomarker
analysis in KDs and fasting resulted in the expected increase in ketones or reduction in insulin-like growth factors,
respectively, however they did not reduce glucose.
Conclusions: Future research with adequately powered studies is required to test the effects of each DR
intervention on treatment toxicities and outcomes. Further research into improving adherence to DR may improve
the feasibility of larger trials.
Background
Pre-clinical studies in model organisms have identified
the potential protective effect of restricting overall en-
ergy intake or specific macronutrient intake on resist-
ance to stress in these models. This has led to a growing
interest in the use of restrictive diets to potentially at-
tenuate the cytotoxic effects of cancer treatments such
as chemotherapy and radiotherapy [1]. Examples of diets
of interest include fasting, which restricts overall energy
intake, and ketogenic diets, which restrict energy intake
from carbohydrate sources. Collectively these diets can
be referred to as dietary restriction (DR) [2].
Cellular metabolism in cancer
When nutrients are not available, non-tumour cells are
able to alter their cell signalling processes, withdrawing
energy from growth/reproduction in order to conserve
their energy for maintenance/repair. This leads to in-
creased cellular protection [3]. This process is partially
mediated by a reduction in growth factors, specifically
insulin-like growth factor-1 (IGF-1) [4]. A reduction in
IGF-1 reduces the activation of the Ras/MAPK and
P13K/Akt pathways that promote expression of genes
involved in proliferation, growth, survival and increased
protein synthesis via mTOR.
Conversely, cancer is a disease associated with dysreg-
ulated metabolism [5]. One of the hallmarks of cancer is
the ability of tumour cells to continue to grow in the ab-
sence of growth factors, such as when nutrients are
scarce [6]. Mutated tumour cells evade these signals due
to gain-of-function mutations in oncogenes (Ras, Akt,
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mTOR), which results in proliferation pathways continu-
ally being active, even in the absence of growth signals
[3]. Therefore, tumour cells do not respond to nutrient
deprivation in the same way as healthy cells and
continue to proliferate, even when nutrients are scarce.
Furthermore, tumour cells are known to rely on
glycolysis for energy production, the phenomenon of
fermenting glucose to form lactic acid, rather than mito-
chondrial oxidative phosphorylation, even in the pres-
ence of oxygen [7]. This process has been coined the
Warburg effect and can be thought of as a trade-off of
“catabolic efficiency for anabolic utility” as the energy
produced by the fermentation of glucose can be used for
biosynthesis required for daughter cells during prolifera-
tion [8, 9]. This metabolic dysregulation is seen in nearly
all tumour cells and may put these cells under increased
pressure when glucose availability is low, requiring cells
to switch from glucose metabolism to ketone metabol-
ism and fatty acid oxidation [10].
This difference in reaction to nutrient scarcity between
healthy and tumour cells is termed differential stress re-
sistance and may render tumour cells more susceptible
to the effects of chemotherapy while at the same time
helping to protect healthy cells against the toxic effect of
chemotherapy [1]. It is thought that through mecha-
nisms such as decreased growth signalling for healthy
cells and the lack of metabolic adaptability found in
tumour cells, DR may lead to the increased vulnerability
of tumour cells to treatment. Therapeutic regimes that
take advantage of this differential stress resistance are
therefore a potential tool in the treatment of cancer.
Dietary restriction (DR)
Methods of DR such as fasting, carbohydrate restriction
or protein restriction are dietary strategies which aim to
exploit this difference in energy metabolism between
healthy and tumour cells [11].
Chronic energy restriction and fasting lead to re-
duced blood glucose and IGF-1 and increased ketones
[12]. However, chronic energy restriction may not be
suitable for patients undergoing treatment with
chemotherapy or radiotherapy due to the increased
risk of cachexia and sarcopenia [3, 10]. Short term
fasting (for example complete energy restriction last-
ing up to 4 days) at the time of chemotherapy has
therefore been suggested as a potential therapy with-
out the risks of chronic energy restriction [2]. More
recently, a fasting mimicking diet has been created
that mimics the physiological effect of fasting without
having to reduce daily energy intake below 725 kcal.
This diet aims to overcome some of the difficulties of
short term, water only fasting, such as issues with ad-
herence, adverse effects and malnourishment [12].
As well as energy restriction, the composition of re-
stricted diets may also be of importance. Ketogenic diets
(KDs) are high in fat with restricted carbohydrate intake.
For example, the 4:1 KD comprises fats in a 4:1 ratio to
carbohydrates, whilst also limiting protein intake, so that
approximately 90% of calories are derived from fat [13].
KDs simulate many of the physiological responses of en-
ergy restriction such as a reduction in blood glucose and
IGF-1 coupled with an increase in ketones [10, 11].
Protein restriction is another form of macronutrient
restriction of interest. Epidemiological research has
found that people following energy unrestricted plant-
based diets, with reduced protein, have lower IGF-1
concentrations than those on long-term severe calorie
restriction with adequate protein. This suggests that
protein restriction may be another therapeutic strat-
egy [14]. Protein restricted diets aim to reduce intake
of total protein or of specific essential amino acids.
Methionine is of particular interest, as an amino acid
that has been recognised to have an important role in
cellular metabolism. It is required for protein synthe-
sis and DNA methylation required in cell growth/pro-
liferation [15].
Previous reviews
Reviews on DR that have been published to date have fo-
cused on subsets of DR studies and not all have been
systematic in their search criteria.
Previous systematic reviews have been conducted in
fasting [16] and KDs [17]. The review of fasting included
studies on the effects of chemotherapy and studies on
tumour progression, without chemotherapy. Authors
concluded that fasting was seen to reduce chemotherapy
side effects and suppress tumour progression. They also
concluded that a 24 h fast may not be long enough for
the protective effects of fasting to apply, due to two hu-
man studies which found less toxicities in 72 h fasts
when compared to 24 h fasts [17, 18]. The review of KDs
was not specifically in populations receiving active treat-
ment for cancer [17]. Authors report inconclusive evi-
dence for changes in nutritional status and adverse
events as well as low adherence to KDs. No systematic
reviews have been conducted on other forms of DR dur-
ing treatment for cancer e.g. fasting mimicking diets or
protein restriction.
In addition to the systematic reviews, two perspective
reviews describing the rationale behind fasting and fast-
ing mimetics at the time of chemotherapy have also
been identified [3, 10]. These reviews describe how the
findings in simple organism and animal models provide
a rationale behind the use of some forms of DR and pro-
vide an overview of previous [3] and ongoing [10] DR
trials. These reviews, however, do not describe a system-
atic search of the literature, and additional studies on
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DR in humans, not included in these reviews, have been
identified.
Unlike a systematic review and meta-analysis, scoping
reviews have a broader scope and provide a description
of current evidence, regardless of quality [18]. This al-
lows research on emerging fields, such as DR during
treatment for cancer, which may not yet have results
from many randomised controlled trials, to be presented
and summarised in a systematic way. As such, a compre-
hensive systematic scoping review to identify studies in
humans looking at the different types of DR at the time
of cancer treatment is warranted. This review will pro-
vide a clear overview of research in this area to date and
identify future research priorities.
Aims and objectives
The aim of this scoping review is to summarise the re-
search on the effects of dietary restriction on cancer
treatment induced toxicities and outcomes in adult pa-
tients undergoing treatment for any malignancy.
The primary objective is to identify and characterise
the research that has been conducted to date on dietary
restriction as an adjuvant therapy in the treatment of
cancer in adults with cancer. The secondary objective is
to explore the acceptability of dietary restrictions in the
samples identified through the search.
Methods
A scoping review protocol was developed and made
publicly available prior to commencement of this re-
view [19].
Inclusion criteria
Inclusion criteria were defined in terms of Population,
Concept and Context [20].
Population
Adult participants undergoing some form of dietary re-
striction as an adjuvant treatment for any type of cancer.
Concept
Any form of dietary restriction studies which assessed:
i) The safety or feasibility of the interventions and/or
ii) The effect of the interventions on outcomes such as
chemotherapy toxicities, clinical outcomes or
cancer biomarkers. Examples of the dietary
restriction forms of interest are short/long term
fasts, intermittent fasts, fasting mimicking diets,
ketogenic diets or protein restriction diets.
Context
Any cancer care setting. The intervention could be deliv-
ered in combination with any standard treatment for can-
cer e.g. chemotherapy, radiotherapy or immunotherapy.
Exclusion criteria
Studies of animal models or model organisms were not
included in this review. Although not specified in our
original protocol, as we were interested in diets that ini-
tiate the metabolic changes associated with differential
stress resistance and not diets that altered macronutrient
composition without aiming to induce such changes,
low fat diets which solely aimed to reduce weight in can-
cer populations were also excluded.
Types of sources
All forms of quantitative and qualitative primary re-
search were included, as were systematic reviews and
meta-analyses. As dietary restriction is an emerging field,
observational studies, case reports and conference ab-
stracts were included in addition to trials. There were no
limitations on date or language of publication.
Search strategy
The following databases were searched for relevant arti-
cles on the 4th January 2018:
1. MEDLINE, Embase, AMED (via OVID)
2. CINAHL
3. Web of Science
An example of the search strategy used in MEDLINE
is shown in Additional file 1 The search terms were up-
dated for each database, in accordance with their specific
requirements.
In addition to the database searches, the reference
lists of all included articles were hand searched for
additional studies alongside relevant systematic re-
views. The ClinicalTrials.gov website was searched to
identify any trials currently taking place which have
not yet been completed or published. As an addition
to the original protocol, the ISRCTN database was
also searched for planned or ongoing trials. Finally,
the first ten pages of google scholar were hand
searched for any additional articles.
The results from the database searches were imported
into an Endnote library and duplicates were removed
during the data screening process.
Selection of studies
Titles and abstracts of the search results were screened
independently by two reviewers from a team of five re-
searchers. Any discrepancies were discussed with a third
reviewer for resolution, if required. Articles identified for
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potential inclusion were retrieved in full for further
screening against the inclusion/exclusion criteria. Full
texts which met the inclusion criteria underwent data
extraction.
Data extraction
Data charting forms were used to extract relevant data
from the included studies. Charting forms were com-
pleted by two reviewers independently, then compared
for accuracy. Extracted data included:
a) Publication Information – Paper title, author
details, publication type, study type, year of study
b) Aims/purpose of the research
c) Study population – sample size, demographics (age,
sex, ethnicity), cancer site and staging, inclusion/
exclusion criteria, withdrawals and exclusions
d) Intervention type and design – Study design,
intervention description (including type, timing and
duration of dietary restriction)
e) Key findings – Outcomes reported, and the
outcome measures used, adverse events, adherence
rates, acceptability and tolerability.
Results
The inclusion flowchart for the review can be seen in
Fig. 1.
The database search retrieved 8448 texts for screening
and 4 additional manuscripts were identified through
hand searches. Title/abstract screening identified 84
texts for full text screening. Fifty were excluded, with
reasons recorded in Fig. 1. Thirty-four full texts which
pertained to 23 studies in total, were identified for inclu-
sion in the review and underwent data extraction.
Characteristics of included studies
The 23 included studies were published between 2007
and 2017 and included a total sample size of 990 (range
1–596 in the observational studies and range 6–73 in
the interventional studies). Four categories of interven-
tions were identified: KDs, fasting, protein restriction
Fig. 1 Inclusion flowchart
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and combined interventions. The majority of studies
were of KD (n = 10), followed by protein restriction (n =
5), fasting (n = 4), and combined interventions (n = 4).
The outcomes reported were varied, ranging from
withdrawal rates, treatment side effects (both standard
treatment and/or intervention effects) and biological
markers. Results were therefore divided into three broad
groups of interest: feasibility, tolerability and treatment
effects. These results are reported for each intervention
category in Tables 1, 2, 3 and 4 described in further de-
tail below. Where adverse events were attributed by
authors to the dietary intervention, they have been in-
cluded under “tolerability”. Where they were reported in
relation to their treatment e.g. chemotherapy side ef-
fects, they are included under “treatment effects”.
Ketogenic diets
Ten studies of KDs that were conducted alongside
treatment for cancer were identified: one randomised
controlled trial (RCT) [21], four single arm trials
[22, 23, 25, 26], one non-randomised, parallel design
trial [27] one case control study [28], one case series
[29] and two retrospective reviews [31, 32]. Four of
the studies also included participants who were not
on any active treatment at the time of the DR [21,
25, 31, 32]. However, as they reported on outcomes
of interest relevant to our research question (e.g.,
adherence) they were included in the review. The
majority of KD studies were in people with brain
cancer (n = 6) and the most common form of diet
was a 4:1 ratio KD (n = 5). The results are sum-
marised in Table 1.
Feasibility results were varied. Of the six interventional
studies, two were terminated early due to poor accrual
and adherence [22, 23]. In the remaining four, the propor-
tion of non-completers ranged from 15 to 71%. Adherence
was reported in two of the interventional studies and was
40% [27] in one study and 80% [21] in the other. However,
although both studies used urinary ketones different cut-
offs were used to assess adherence.
Weight loss, adverse events and reasons for dis-
continuation of diet were the main tolerability
outcomes reported. In general, weight loss was not a
cause for concern on the KDs used, with loss
remaining below 10% of initial body weight in the
majority of participants. Two trials also broke down
weight lost into loss of fat mass and fat free mass.
Both found that in spite of weight loss, fat free mass
was preserved [21, 29]. Reports of grade 3/4 adverse
events were rare.
Intervention effects reported included markers of me-
tabolism such as ketones, glucose and insulin, quality of
life and treatment- related adverse events. Of the seven
studies that reported on ketones or βeta-hydroxybutyrate
specifically (a common ketone), all reported ketosis or an
increase in ketones in those on the KD. However, this was
not always linked with a corresponding reduction in blood
glucose [21, 25, 26, 29]. Champ et al is the exception
which found a reduction in blood glucose on KD during
radiotherapy, even though participants received steroidal
treatment which is known to increase blood glucose [28].
Four studies reported on quality of life [21, 25, 29, 32]
with one finding evidence of positive effects [21], one find-
ing negative effects [25] and one finding no effect [29].
We were unable to extract results from the fourth study
as they were not stratified by diet type [32].
Protein restriction
Five studies of protein restriction were identified, of
which four were specifically methionine (MET)-re-
stricted (Table 2). One study was an RCT in people with
prostate cancer [33] while the remaining four were clin-
ical trials with single arm allocation [34–37] including
people with melanoma, glioma and colorectal cancer.
One of the single arm trials was a phase 1 trial [36]
which was followed by a phase 2 trial [37].
MET free diets were delivered as oral powders which
participants consumed as drinks. Three of the four
MET-free diet studies reported on the mean adherence
to the diet which ranged from 72.4 to 92.5% [34, 35, 37].
Feasibility findings were not reported in the RCT of a
protein restricted diet [33].
Tolerability was reported in three trials of the MET
restriction. There were no changes in markers of nu-
tritional status (body weight, albumin or pre-albumin)
associated with the MET-free diet [34, 35, 37]. In the
protein restricted diet trial, the intervention group
lost weight, but this was an aim of the trial which
recruited overweight participants [33].
The main outcome of interest within the MET restric-
tion studies was blood MET concentration. All four tri-
als of MET-free diet resulted in a reduction in mean
plasma MET concentrations (reductions ranged from
40.7 to 53.1%) which authors reported as successful re-
duction rates [34–37]. Outcomes of interest in the total
protein restriction trial were cellular effects of the diet,
specifically the effect of the diet on molecular mediators
in extracellular vesicles. They found that the diet in-
creased the levels of extracellular vesicle-associated lep-
tin receptors and a higher Y/S Insulin receptor
substrate-1 ratio in the protein restricted group, indicat-
ing improved leptin and insulin sensitivity [33].
Fasting
Four studies of fasting were identified, and all were con-
ducted at the time of chemotherapy: One pilot RCT
[38], one dose escalating study [40], one qualitative study
[41] and a case series report [43] (Table 3). Each study
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Table 3 Fasting results
Reference
(author,
year)
Design Population (no. of
participants, cancer
site, treatment)
Intervention (DR
intervention,
corresponding cancer
treatment)
Feasibility Tolerance Treatment effect
De Groot
2013 and
2015,
Netherlands
[38, 39]
Pilot RCT 13 (7 IG, 6 CG)
IG: Median age 51y
(range 47-64y)
CG: Median age 52y
(range 44-69y)
Stage 2–3 breast
cancer
48 h fast (24 h before
until 24 h after start of
chemotherapy)
3 weekly (neo)
adjuvant TAC-
chemotherapy
15% withdrawal NR ↑ median blood glucose (mmol/L);
IG: 5.2 to 6.8 (p = 0.042), CG: 4.8 to
7.0 (p = 0.043)
↓ mean IGF-1 (nmol/L) of 17% in
IG (23.7 to 19.6, p = 0.012), ↔ CG
↔ median insulin (mU/L) in IG, ↑
in CG group: 2.0 to 16.0 (p = 0.043)
↔ TSH (mU/L) in IG: 1.49 to 0.42, ↓
in CG: 1.38 to 0.61 (p = 0.034)
↔ in IGF-BP3 or FT4
↑ erythrocytes in IG (Day 7: p =
0.007, 95% CI 0.106–0.638; Day 21:
p = 0.002, 95% CI 0.121–0.506)
↑ thrombocytes in IG (p = 0.00007,
95% CI 38.7–104) at day 7
↔ leukocytes or neutrophils
↔ self-report side effects
Dorff, 2016
and Quinn,
2013, USA
[40]
Dose
escalation
20
Median age 61y
(range 31–75y)
Any cancer
3 cohorts fasted before
chemotherapy for 24,
48 and 72 h (divided as
48 pre-chemo and 24
post-chemo)
Platinum based
chemotherapy
Adherence: 24 h
fast: 67%, 48 h fast:
83%, 72 h fast 57%
Grade 1/2 fatigue,
headache, dizziness,
hypoglycaemia,
weight loss,
hyponatremia and
hypotension
No grade 3/4 fasting-
related toxicities
5% failed to regain
25% of weight lost
↓ IGF1. 24 h fast: Cycle 1: − 30%
(− 12 to − 44%) Cycle 2: − 31% (−
45% to − 13%) 48 h fast: Cycle 1:
− 33% (− 45% to − 18%) Cycle 2:
− 20% (− 37 to 1%) 72 h fast: Cycle
1: − 8% (− 24 to 13%) Cycle 2: 16%
(− 5 to − 42%)
↔ glucose
↓ mean insulin. 24 h fast: − 56%.
48 h fast: − 27%. 72 h fast: − 42%
at 48 h (data at 72 h NR)
↓ DNA damage in 48 h and 72 h,
but not 24 h fast
↓ nausea. 24 h fast: 100%, 48 h fast:
87%, 72 h fast: 43% (p = 0.019)
↓ vomiting. 24 h fast: 83%, 48 h
fast: 43%, 72 h fast: 0% (p = 0.003)
↔ neutropenia. 24 h fast: 67%, 48
h fast: 14%, 72 h fast: 29% (p =
0.17)
Mas, 2017,
France [41]
Qualitative 15
Age NR
Breast cancer
Self-administered fast
concurrent to
chemotherapy
Main motivation to
limit chemotherapy
side effects
Effect of fasting on
tumour was not a
motivation (patients
felt cancer-free
following surgery)
Offered a chance for
ppts to take an
active role in
treatment
13% reported AEs
which stopped them
fasting
Fasting was a positive experience
that reduced the side effects of
chemotherapy and reinforced self-
esteem
Safdie, 2009
and [42],
USA [43]
Case
series
10
Median age 61y
(range 44-78y)
Breast (n = 4), prostate
(n = 2), ovarian (n = 1),
uterine (n = 1), lung
(n = 1), oesophageal
(n = 1) cancer
Self-administered fast
ranging from 48 to
140 h prior to and/or
5–56 h following
chemotherapy
NR Low grade dizziness,
hunger, and
headaches reported
No grade 3/4
toxicities
Weight loss recovered
in “most” patients
↓ in fatigue (p < 0.001), weakness
(p < 0.00193) and GI side effects
(absent) in 46 reported cycles with
fasting compared with 18 ad-
libitum cycles
↑ = increase/higher
↓ = reduction/lower
↔ = no change/no difference
Where absolute figures were provided, %s have been calculated to aid comparison
Abbreviations: AEs Adverse Events, CG Control Group, CHO Carbohydrate, DR Dietary Restriction, FT4 thyroxine, GI, gastrointestinal, IG Intervention
Group, IGF Insulin-like Growth Factor, IGFBP Insulin-like Growth Factor Binding Protein, NR Not Reported, RCT Randomised Controlled Trial, SAEs Serious
Adverse Events, TSH Thyroid Stimulating Hormone
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utilised a different fasting protocol. Self-administered
fasts ranged from 48 to 140 h prior to and/or 5–56 h fol-
lowing chemotherapy. Per-protocol fasts ranged from
24 h prior to chemotherapy to 72 h, divided as 48 h prior
to chemotherapy and 24 h post-chemotherapy. Each
study also included a different clinical population, with
varying cancer types.
Feasibility findings were reported in both interven-
tional studies with the pilot RCT reporting a 15% (n = 2)
withdrawal rate [38]. Within the dose escalation study,
authors reported 67% compliance in the 24 h fast, 83%
in the 48 h fast and 57% in the 72 h fast. However, they
also note that, although self-reported compliance was
high in the 72 h fast, it may have been subject to poorer
compliance given that the IGF analysis showed lower
than expected reductions in IGF1 at 72 h [40].
Tolerability of the fast was not discussed in the RCT.
However, no grade 3/4 toxicities were reported among
participants in the dose-escalating or qualitative studies
[40, 43]. Grade 1/2 toxicities are listed in Table 3 and in-
cluded dizziness, hunger, headaches and weight loss.
Among the participants in the qualitative study, 13%
(n = 2) reported experiencing adverse events which
stopped them following their self-administered fast [41].
In the case series, weight loss was reported to resolve in
“most” participants following introduction of normal
feeding [43]. Only 1 participant in the dose escalation
study did not regain at least 25% of body weight last
during the fast between cycles and was unable to con-
tinue with the second fast, as per the trial protocol [40].
The intervention effects of interest within the fasting
literature focus on biological markers of metabolism and
chemotherapy toxicities. Both interventional studies found
a reduction in IGF1 associated with fasting, however the
levels were varied depending on the trial and length of the
fast. Reductions ranged from 17.3% after 24 h of the 48 h
fast [38] to 33% after the 48 h fast [40]. Despite fasting,
neither interventional study found a reduction in glucose,
with glucose increasing after 24 h in the RCT [38] and no
changes evident in the dose escalation study [40]. Study
authors suggested the use of steroidal treatment among
study participants as a potential reason for the lack of
glucose reduction during fasting. The two observational
studies found evidence of decreased side effects from
chemotherapy. This was self-reported in the qualitative
study [41] (side effects that were reduced were not speci-
fied) while the case series report found a reduction in
fatigue, weakness and gastrointestinal side effects in cycles
completed alongside a fast when compared to cycles
where cases ate ad-libitum [43]. These findings were simi-
lar in the dose escalating study which found a trend for
reduced nausea and vomiting in longer fasts [40] but were
not seen in the pilot RCT which found no differences in
self-reported AEs between groups [38].
Combined interventions
Four studies of combined interventions were identi-
fied and are summarised in Table 4: One RCT [44]
and three case reports [46–48]. All combined some
form of ketogenic or low carbohydrate diet with
additional interventional aspects such as increased
physical activity in the RCT [44], or additional dietary
changes [46–48]. As the diets were delivered in com-
bination with other components and the majority are
based on single patient case reports, interpretation is
limited. However, the RCT reported a high retention
rate of 81% and found that the main side effect
associated with the low carbohydrate and increased
physical activity intervention was mild headaches [44].
Ongoing/planned trials
The clinicaltrials.gov and ISRCTN databases were
searched on 10th December 2018 for studies that
were registered as ongoing or planned. This search
identified: 13 trials of KD, one trial of a KD com-
bined with short term fasting, one trial of short term
fasting, five trials of fasting-mimicking diets and two
trials of intermittent fasting. These are summarised in
Table 5. This search indicates that the KD continues
to be the most researched form of restriction (n = 13)
and the majority of these studies are in people with
brain cancer (n = 8). Although there are an increasing
number of KD RCTs identified (n = 5), three specific-
ally identify as pilot/feasibility studies, and all have
small target sample sizes (range = 12–60). An in-
creased interest in other forms of fasting such as
intermittent fasting (n = 2) and fasting-mimicking di-
ets (n = 5) is also evident. Fasting RCT target sample
sizes range from 30 to 250.
Discussion
Main findings
Few studies have been published on DR during treat-
ment for cancer to date, particularly when the data are
stratified by restriction type. More studies are currently
in progress and due to complete recruitment within the
next 3 years, which identifies DR as a research area of
growing interest. However, most ongoing trials are early
stage studies with small sample sizes. These may allow
us to further understand the feasibility of conducting
such studies but will not enable conclusions to be drawn
about the efficacy of these interventions. Large studies
with long-term outcomes are needed to definitively
address these questions.
Our findings show that the most commonly studied
form of dietary restriction is the KD. As with the previ-
ous review of KD in adults with cancer not specifically
receiving treatment for cancer, we found the 4:1 diet to
be the most common form being used in conjunction
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with treatment [17]. The previous review concluded that
adherence rates were low, and our review confirms the
potential issues surrounding adherence when using KD
alongside treatment for cancer. Adherence results were
varied, with different definitions of adherence and toler-
ability used, making comparisons of adherence to the
different forms of the KD difficult. This, in combination
with the early termination of two of the KD trials, sug-
gest that further research into improving acceptability of
KDs may be warranted. For example, there could be the
potential for improved adherence and retention in KD
studies with lower ratios of fat:carbohydrate than the 4:1
diet whilst still achieving favourable metabolic changes
[26]. Furthermore, as most studies of KD reported few
issues with tolerability and weight loss, it is possible that
there could be issues with palatability or sustainable be-
havioural change.
The results of protein restriction research suggested
that MET-free diets were adhered to well with limited
tolerability issues. However, the diets were provided over
a short amount of time as oral solutions. It is less clear
how well general protein restriction as part of a low pro-
tein meal-based diet is adhered to, as only a single trial
of overall protein restriction has been conducted, which
did not report feasibility outcomes.
Very few studies of fasting have been conducted. Over-
all, the studies to date have found that participants are
able to follow short-term fasts, although length of
interventions varied, and it is unclear whether longer
fasts have lower adherence. As with the other dietary
restriction methods, adverse events related to fasting did
not appear to affect adherence in the majority of studies,
with the exception of the qualitative study [41]. This
may be because participants in that study were self-ad-
ministering the fast and not receiving clinical support.
As with the research on KDs, fasting appears to result in
a reduction in IGFs. However, it remains unclear
whether it also results in a decrease in blood glucose.
This may be due to steroidal treatment received along-
side chemotherapy, which is known to increase blood
glucose levels. One interventional and two observational
studies found some evidence of reduced toxicities in
fasted participants, however the evidence is limited by
the small number of trials and small sample sizes
included.
Future research
Larger, adequately powered RCTs will be required in
order to study the efficacy of each DR intervention type
to reduce treatment side effects or improve outcomes.
Within KD research, further exploration of issues associ-
ated with adherence is warranted if larger trials are to
test this intervention. There is a current lack of in-depth
qualitative work conducted in this area, which may help
in exploring the reasons for non-compliance in trials,
especially if tolerability is high.
While research into MET-free diets suggest that tri-
als of this intervention are feasible, definitive RCTs
with larger sample sizes are required to ascertain
whether these diets result in reduced treatment side
effects or improved outcomes. Further research into
adherence to and tolerability of general protein
restricted diets is required in order to understand the
feasibility of conducting this form of intervention
alongside treatment of cancer. It is also not clear
whether this diet could be introduced to people with
normal weight without resulting in significant weight
loss, as the only trial to date was in people who were
overweight.
Conflicting findings regarding blood glucose levels
suggest further research into the effect of dietary restric-
tion on this marker is required. Attention should also be
paid to the use of steroidal treatment alongside chemo-
therapy, to investigate whether increased blood glucose
seen with these drugs inhibits the potentially protective
effect of dietary restriction. In a current study of fasting-
mimicking diets the investigators have chosen to omit
dexamethasone treatment [39]. However, on a pragmatic
level, it would also be of interest to explore whether IGF
reduction alone is able to induce metabolic changes that
would be sufficient to achieve a reduction in toxicity,
even in the presence of dexamethasone. Particularly as
two observational and one interventional study found
some evidence for reduced side effects when chemother-
apy was provided as standard. Reporting on the type of
weight-loss resulting from the fast would also be of
interest, to ascertain whether fat is lost while lean
muscle mass is retained, as has been the case in KDs.
Strengths and limitations
While some aspects of dietary restriction have been
reviewed previously [16, 17], this scoping review
employed a systematic search of the literature on the
different forms of dietary restriction during treatment
for cancer, to collate the research to date. Although
every effort was made in the search to identify all
relevant texts, it is possible that some studies of DR dur-
ing treatment for cancer have been missed.
In order to acknowledge the emerging nature of DR
research, a scoping review process was followed,
which included data from observational and single-
arm studies. This allowed us to consider the breadth
of previous research in an emerging field, helping to
inform future studies. However, this also means that
the quality of studies has not been assessed against
the standards commonly used in systematic reviews of
RCTs. This approach has allowed us to summarise
the emerging research on DR in cancer treatment and
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highlights some issues that should be considered
when designing further studies in this area.
Conclusion
DR regimes are a potential tool to help reduce the
toxicities associated with cancer treatment. However, the
limited number of studies to date have had small samples
and have not been designed to specifically test the efficacy
of these interventions. DR is, however, a growing research
area with further trials being conducted. Definitive RCTs
are required to assess the efficacy of DR during cancer
treatment on reducing treatment related toxicities or
improving treatment outcomes. This scoping review has
highlighted the potential problem of adherence issues and
as such suggests further research into improving dietary
compliance is conducted before larger efficacy trials are
conducted. Further research into the effect of DR
interventions on cellular metabolism when used in com-
bination with treatment is also warranted.
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